Roche"s Genentech Inc. announced on April 22 that according to the latest results of a clinical trial, Avastin (bevacizumab) failed to prevent colon cancer from recurring. The trial followed 2,700 patients who received 6 months of standard chemotherapy or 6 months of that chemotherapy with additional Avastin. The trial results will be presented at the American Society of Clinical Oncology meeting next month.